1. Late to the Game
    Jim Harrison Jim Harrison United States says:
    September 2, 2021 at 12:15 PM

    Pfizer and Merck are late to the game.  Oramed Pharmaceuticals (NASDAQ:ORMP). Has been working on an Oral pill for some time. The first trial involved 24 unvaccinated volunteers, each taking one or two pills, before moving on to larger Phase 3 trials. The vaccine should be "much more resistant to COVID-19 variants," according to Oramed CEO Nadav Kidron, since it trains the immune system against three viral proteins instead of the single protein targeted by Pfizer and Moderna's (NASDAQ:MRNA) shots.

    Reply
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback